Drug intelligence / Profile preview

HUC2-344

Development stage: Unknown
Lead developer: Huons
Modality: Small Molecules
Administration: Oral

Overview

HUC2-344 is an incrementally modified chemical drug under development by Huons for the treatment of diabetes mellitus. It is classified as an antihyperglycaemic agent, but its precise mechanism of action has not been defined in public sources. The drug is not considered a new molecular entity and does not have orphan drug status. Clinical development has reached Phase 1 in South Korea, with completed trials evaluating its pharmacokinetics and safety both as a single agent and in co-administration with related compounds (HUC2-344-R1 and HUC2-344-R2)[1][2][6].

Beyond the preview

Go deeper on HUC2-344.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUC2-344.

Explore the full profile